ReviewAntibiotics (Basel, Switzerland)2019
The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies.
Review in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- NewTheScientificWorldJournal · 2025Pooled it
- Enhancing Antimicrobial Efficacy: The Role of Metal Complexation in Chitosan-Based Antimicrobial Agents.Applied biochemistry and biotechnology · 2026Review
- Article
- Review
- Phyto-Assisted Synthesis of Silver Nanoparticles (Ag-NPs) Using Delonix elata Extract: Characterization, Antimicrobial, Antioxidant, Anti-Inflammatory, and Photocatalytic Activities.Molecular biotechnology · 2026Article
- Morin-functionalized pHEMA cryogel membranes for combating MDR Escherichia coli and MRSA: antibacterial efficacy and molecular docking study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Eco-friendly synthesis of an antimicrobial polymer (1,4-bis(methacryloyl)piperazine) via maghnite catalysis:Frontiers in chemistry · 2026Article
- Comparative transcriptomics analysis of theBiofilm · 2025Article
- Towards Safe and Effective Biomedical Nanocoatings: Plasma-Sputtered Magnesium-Based Nanoparticles with Cytoprotective, Antimicrobial and Antialgal Properties.Molecules (Basel, Switzerland) · 2025Article
- Review
- Deciphering meropenem persistence inAntimicrobial agents and chemotherapy · 2025Article
- Emerging Nanotechnological Applications in Preserving and Improving the Shelf Life of Food.Pharmaceutical nanotechnology · 2025Review
- Standardization of the Agar Plate Method for Bacteriophage Production.Antibiotics (Basel, Switzerland) · 2024Article
- Essential Oil of Fractionated Oregano as Motility Inhibitor of Bacteria Associated with Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Article
- Optimization of polysaccharide conditions and analysis of antioxidant capacity in the co-culture ofPeerJ · 2024Article
- Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance.Frontiers in microbiology · 2024Review
- The Impact of Adding Chitosan Nanoparticles on Biofilm Formation, Cytotoxicity, and Certain Physical and Mechanical Aspects of Directly Printed Orthodontic Clear Aligners.Nanomaterials (Basel, Switzerland) · 2023Article
- Blue 405 nm LED light effectively inactivates bacterial pathogens on substrates and packaging materials used in food processing.Scientific reports · 2023Article
- Integration of Antimicrobials and Delivery Systems: Synergistic Antibiofilm Activity with Biodegradable Nanoemulsions Incorporating Pseudopyronine Analogs.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
Pathogenic antibiotic resistant bacteria pose one of the most important health challenges of the 21st century. The overuse and abuse of antibiotics coupled with the natural evolutionary processes of bacteria has led to this crisis. Only incremental advances in antibiotic development have occurred over the last 30 years. Novel classes of molecules, such as engineered antibodies, antibiotic enhancers, siderophore conjugates, engineered phages, photo-switchable antibiotics, and genome editing facilitated by the CRISPR/Cas system, are providing new avenues to facilitate the development of antimicrobial therapies. The informatics revolution is transforming research and development efforts to discover novel antibiotics. The explosion of nanotechnology and micro-engineering is driving the invention of antimicrobial materials, enabling the cultivation of "uncultivable" microbes and creating specific and rapid diagnostic technologies. Finally, a revival in the ecological aspects of microbial disease management, the growth of prebiotics, and integrated management based on the "One Health" model, provide additional avenues to manage this health crisis. These, and future scientific and technological developments, must be coupled and aligned with sound policy and public awareness to address the risks posed by rising antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.